FCGR3A Recombinant Monoclonal Antibody

Code CSB-RA008543MA1HU
Size US$210
Order now
  • Immunofluorescence staining of Hela cell with CSB-RA008543MA1HU at 1:30, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
CD 16 antibody; CD 16a antibody; CD16 antibody; CD16a antibody; CD16a antigen antibody; CD16B antibody; CD16b antigen antibody; Fc fragment of IgG antibody; Fc fragment of IgG low affinity IIIa receptor (CD16) antibody; Fc fragment of IgG low affinity IIIa receptor antibody; Fc fragment of IgG receptor IIIa antibody; Fc fragment of IgG; low affinity III; receptor (CD16) antibody; Fc fragment of IgG; low affinity III; receptor for (CD16) antibody; Fc fragment of IgG; low affinity IIIa; receptor (CD16) antibody; Fc fragment of IgG; low affinity IIIa; receptor (CD16a) antibody; Fc fragment of IgG; low affinity IIIa; receptor for antibody; Fc fragment of IgG; low affinity IIIb; receptor (CD16b) antibody; Fc fragment of IgG; low affinity IIIb; receptor for (CD16) antibody; Fc gamma R3 antibody; Fc gamma receptor III 2 (CD 16) antibody; Fc gamma receptor III A antibody; Fc gamma receptor IIIA antibody; Fc gamma receptor IIIb (CD 16) antibody; Fc gamma RIII alpha antibody; Fc gamma RIII antibody; Fc gamma RIII beta antibody; Fc gamma RIIIa antibody; Fc gamma RIIIb antibody; Fc of IgG antibody; Fc-gamma receptor III2 (CD 16) antibody; Fc-gamma receptor III2 (CD16) antibody; Fc-gamma receptor IIIb (CD16) antibody; Fc-gamma RIII antibody; Fc-gamma RIII-alpha antibody; Fc-gamma RIIIa antibody; FCG 3 antibody; FCG3 antibody; FCG3A_HUMAN antibody; FCgammaRIIIA antibody; FCGR 3 antibody; FCGR 3A antibody; FCGR3 antibody; FCGR3A antibody; FCGR3A protein antibody; FCGRIII antibody; FCGRIII-2 antibody; FcR 10 antibody; FcR-10 antibody; FcR10 antibody; FcRIII antibody; FcRIIIa antibody; IGFR 3 antibody; IGFR3 antibody; IgG Fc receptor III 1 antibody; IgG Fc receptor III 2 antibody; IgG Fc receptor III-2 antibody; IMD20 antibody; immunoglobulin G Fc receptor III antibody; immunoglobulin G Fc receptor III-2 antibody; Low affinity IIIa receptor antibody; Low affinity immunoglobulin gamma Fc region receptor III A antibody; Low affinity immunoglobulin gamma Fc region receptor III-A antibody; Low affinity immunoglobulin gamma Fc region receptor IIIB antibody; neutrophil-specific antigen NA antibody
Species Reactivity
Recombinant Human FCGR3A protein
Immunogen Species
Homo sapiens (Human)
Rabbit IgG
Clone No.
Purification Method
It differs from different batches. Please contact us to confirm it.
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Tested Applications
Recommended Dilution
Application Recommended Dilution
IF 1:20-1:200
Troubleshooting and FAQs
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

The production of the FCGR3A recombinant monoclonal antibody initiates with the acquisition of FCGR3A antibody genes. These genes are then introduced into suitable host cells, which are cultured for synthesizing FCGR3A antibodies using a cell-based expression and translation system. This approach offers numerous advantages, including a substantial improvement in the purity and stability of the resultant FCGR3A recombinant monoclonal antibodies, along with enhancements in antibody affinity and specificity. Subsequent to synthesis, the FCGR3A recombinant monoclonal antibody undergoes purification via affinity chromatography. It is recommended for use in ELISA and IF. This antibody exclusively targets the human FCGR3A protein.

FCGR3A is an important receptor involved in the recognition and response to antibodies, particularly in ADCC and phagocytosis. Its activation on immune cells is a key mechanism for targeting and eliminating infected or abnormal cells and pathogens, contributing to the body's defense against infections and cancer.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.
Gene References into Functions
  1. Conditioned media or microparticles released from obese omental adipose tissue increased CD16 and CCR5 expression on CD14(+)CD16(-) monocytes and augmented their migratory capacity towards the conditioned media from obese omental adipose tissue, itself. PMID: 27677832
  2. results showed no association between FCGR3A 158V/F alleles and susceptibility to systemic lupus erythematosus PMID: 27914599
  3. High CD16(+) Monocyte is associated with Acute Rejection after Liver Transplantation. PMID: 29970436
  4. The analysis of Fc gamma receptor FCgammaRIIIA 158 V/f gene polymorphism showed that all 100 immune thrombocytopenic purpura (ITP) patients carry the wild FcgammaRIIIa (FF) genotype. PMID: 28856973
  5. CD16- monocyte subsets are upregulated in systemic lupus erythematous patients and may have a role in pathogenesis and development of this disease PMID: 28821990
  6. CD16 expression and morphological maturity of neutrophils are associated with higher iron ferritin levels in major beta-thalassemia. PMID: 29729700
  7. we propose a system of FCGR3A regulation in human NK cells in which CpG dinucleotide sequences and concurrent DNA methylation confer developmental and cell type-specific transcriptional regulation, whereas miR-218 provides an additional layer of posttranscriptional regulation during the maturation process. PMID: 29229679
  8. The study revealed that CD16-CD68-expressing macrophages appear to participate in ureteral neoplastic transformation. PMID: 29243545
  9. FCGR3A V158F polymorphism seems to be associated with anti-drug antibodies production against monoclonal antibodies targeting tumor necrosis factor (TNF) and it could be taken into account when considering the dose and type of anti-TNF in inflammatory bowel diseases patients. PMID: 29333082
  10. The study first identified that CNVs in the FCGR3A gene were associated with the risk of gout, and the CNV in the locus showed different distributions of frequency between gout patients and healthy subjects, particularly the frequency of the high FCGR3A copy number variant. PMID: 28405828
  11. Affimer proteins inhibit immune complex binding to FcgammaRIIIa with high specificity through competitive and allosteric modes of action. PMID: 29247053
  12. analysis of the assembly and surface expression of FcepsilonR1alpha in cells shows that CD16A associates equally well with human CD247 and FcepsilonR1gamma homodimers PMID: 28652325
  13. low copy numbers of FCGR2A and FCGR3B to be common risk factors for systemic lupus nephritis (SLE) and ANCA-associated systemic vasculitis (AASV). PMID: 28355982
  14. Memory-like differentiation resulted in enhanced IFN-gamma production triggered by leukemia targets or FcgammaRIIIa ligation within licensed NK cells, which exhibited the highest functionality of the NK cell subsets interrogated. PMID: 27894857
  15. We developed a semi-mechanistic model including a target-mediated elimination component that accurately described rituximab PK in patients with CLL. This allowed us to show for the first time an influence of a baseline count of target antigen and the FCGR3A-158V/F polymorphism on rituximab target-mediated elimination. PMID: 27783363
  16. FCGR3A-V158F polymorphism could be a specific marker for response to anti-TNFalpha therapy in psoriasis patients. PMID: 27044681
  17. The FCGR3A V allele correlated with the occurrence of late-onset neutropenia following rituximab treatment in patients with rheumatic diseases PMID: 28270182
  18. association between the antibody-dependent cellular cytotoxicity activity of adalimumab, an IgG reagent, in combination with FcgammaRIIIa -158V/F polymorphism (rs396991) PMID: 28913867
  19. CXCR7 mediates CD14(+)CD16(+) monocyte transmigration across the blood brain barrier, and is a potential therapeutic target for neuro AIDS. PMID: 28754798
  20. KIR/HLA-C complex and CD16A (48H/R/L,158V/F) gene polymorphisms in 52 colorectal cancer patients and 61 local healthy controls, are reported.. PMID: 27519478
  21. These data suggest a role for FcgammaRIIIa-pSyk cosignaling in modulating NA-TLR responses in human CD4(+) T cells by affecting the amounts and cellular distribution. These events are important for understanding of autoimmune pathology. PMID: 28500073
  22. This study demonstrated that no association between FCGR3A polymorphisms in Guillain-Barre Syndrome in a Brazilian population. PMID: 27609290
  23. Intermediate CD14++CD16+monocytes might be closely related to the pathogenesis of atrial fibrillation and reflect functional remodelling of the left atrium. PMID: 26826137
  24. Association between FcgammaRIIIa genetic polymorphisms and susceptibility to severe malaria anemia in children in western Kenya. PMID: 28427365
  25. FcgammaRIII3a-131H allele has a protective role in autoantibody production in Chinese rheumatoid arthritis patients. PMID: 28112584
  26. used a combination of NMR and 1 mus all-atom computational simulations to identify unexpected contacts between the N45 N-glycan and CD16A polypeptide residues PMID: 28613884
  27. We conclude that FCGR3A CNVs are a major risk factor for female sarcoidosis and FCGR3B CNVs may also affect the development of sarcoidosis. PMID: 27059607
  28. FcgammaRIIIa V allele-restricted pathological complete response benefit from neoadjuvant trastuzumab plus lapatinib in HER2+ breast cancer. PMID: 27378608
  29. CD16+ cells were significantly more frequent among Natural Killer (NK) cells negative for the inhibitory KIR (iKIR) KIR2DL1, KIR2DL3, and KIR3DL1 than those positive for any one of these iKIR to the exclusion of the others, making iKIR+ NK cells poorer antibody dependent cellular cytotoxicity effectors than iKIR- NK cells. PMID: 27732638
  30. The association of CD16a-inducible NK cell-selective transcripts CD160 and XCL1 with kidney biopsies with antibody-mediated rejection provides evidence for NK cell CD16a activation in AMR. PMID: 27906829
  31. expression of FcgammaR was not different between immune thrombocytopenia (ITP) and controls; the FCGR3A (158V/F) polymorphism, known to increase the affinity of FcgammaRIII to IgG, was over-represented in ITP patients PMID: 28142207
  32. Increased fraction of CD16(high) CD62L(dim) neutrophils was shown to correlate with an increased survival rate. PMID: 28247912
  33. Trastuzumab acidic variants had lesser binding to oncogene protein HER-2 (HER2) in comparison to the basic variants, and both acidic and basic variant showed no significant changes in their binding to soluble CD16a receptors. PMID: 28087106
  34. this study shows that FcgammaR single nucleotide polymorphisms are predisposing factors for urinary tract infections after kidney transplantation PMID: 28315348
  35. FCGR3A expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
  36. this study shows that genetic polymorphisms located within an enhancer FCGR3A influence NK cell-mediated antibody-dependent cellular cytotoxicity PMID: 27338556
  37. CD16a resided in Kupffer cells, and it contributed to the inhibition of the growth of liver tumor cells. PMID: 27082928
  38. FcgammaRIIIA allelic distribution was similar among pediatric Guillain-Barre syndrome patients and controls. PMID: 27064330
  39. Anti-platelet drugs exert an immunomodulatory action by counteracting CD14(high)CD16(+) monocyte increase under pro-inflammatory conditions, with this effect being dependent on the amplitude of P-selectin reduction. PMID: 27118470
  40. analysis of natural killer cell markers in renal transplantation that have roles in acute rejection reveals that CD56 and CD57 are increased in the interstitial compartment in donor-specific antibody (DSA)-negative biopsies from patients with acute antibody-mediated rejection without C4d, and CD16 is increased in the glomerular compartment in DSA-positive biopsies PMID: 26615051
  41. Studies suggest that the Fc gamma receptor IIIA (FCGR3A) 158 V/F polymorphism can predict the treatment response to rituximab-based chemotherapy in non-Hodgkin lymphoma (NHL) patients. PMID: 27431582
  42. The incidences of the FCGR3A-158 variants VV, VF, and FF for nine patients with relapse were 0 (0 %), 8 (89 %), and 1 (11 %) compared to 13 (11 %), 61 (52 %), and 44 (37 %) in the 118 patients without relapse. PMID: 27376362
  43. Of 36 DLBCL patients, the distributions of F/F, V/F, and V/V types of alleles of FcgammaRIIIA were 25%, 50%, and 25%, respectively. The overall survival in the F/F allele group was found to be lower than in the other 2 groups, but the overall response rates were similar for all groups. PMID: 26316483
  44. Lower copy numbers (PMID: 26494566
  45. This metaanalysis indicates that polymorphisms in the pathways of immune complex clearance, such as the FcgammaRIIIa, FcgammaRIIIb, and ITGAM genotypes, are potential susceptibility genes for neuropsychiatric systemic lupus erythematosus. PMID: 26773105
  46. Data suggest a mechanism for the increased affinity of GASDALIE Fc for Fc receptor FcgammaRIIIa. PMID: 26850169
  47. Single-nucleotide polymorphisms of FCGR3A gene is associated with bloodstream infections After Liver Transplantation. PMID: 26517570
  48. These results suggest that the structure and expression of the CD16 molecule differs among FcgammaRIIIa-V158F genotypes, and the FcgammaRIIIa-V158F polymorphism may be represent a haplotype with other SNPs in regulatory regions in Japanese subjects. PMID: 26582002
  49. our method allows determining the CNV status of the FCGR locus, we identified association of CNV in FCGR3B to RA and showed a functional relationship between CNV in the FCGR3A gene and CD16A expression. PMID: 25966632
  50. KRAS wild chemorefractory metastatic colorectal cancer patients with genotype FF of V158F can benefit from cetuximab based therapy PMID: 26363448

Show More

Hide All

Involvement in disease
Immunodeficiency 20 (IMD20)
Subcellular Location
Cell membrane; Single-pass type I membrane protein. Secreted. Note=Exists also as a soluble receptor.
Tissue Specificity
Expressed on natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placental trophoblasts.
Database Links

HGNC: 3619

OMIM: 146740

KEGG: hsa:2214

STRING: 9606.ENSP00000356946

UniGene: Hs.372679

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join Us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To